| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | 55% total growth, 17% organic base business growth. |
|---|---|
| Margins | EBITDA margins expanded to 33.8% due to merger cost synergies. |
| Demand visibility | Strong chronic demand in India; base business outperforming IPM growth. |
| Management confidence | Balanced; optimistic on synergies but admits Brazil Semaglutide delay miss. |
Growth
Revenue grew 55%, with JB merger contributing significantly. Organic growth led by Brazil (27%) and India (19%).
Outlook
Guided double-digit growth for JB India RX business; net debt/EBITDA stands at 2.07x.
Risks
Semaglutide supply setback in India and loss of first-mover advantage for Semaglutide in Brazil.
Earnings Call Transcript filed with NSE, NSE: TORNTPHARM. Summary written with AI assistance from the document.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,772.00
- Market cap
- ₹1,81,512 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 83.2×Sector 47.4×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.97%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Annual General Meeting
Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals Limited has been assigned an ESG rating of 70 by NSE Sustainability Ratings and Analytics Limited. This independent assessment follows SEBI's regulatory framework for ESG Rating Providers.
Torrent Pharmaceuticals Annual General Meeting
Torrent Pharmaceuticals issued a Postal Ballot notice to shareholders for the appointment of Shanti Ekambaram as an Independent Director. Voting concludes on September 6, 2026.
Torrent Pharmaceuticals Other Announcement
Torrent Pharmaceuticals submitted a statement under Regulation 52(7) & (7A) regarding the utilization of issue proceeds for the quarter ended June 30, 2026.
Torrent Pharmaceuticals Q1 FY27 Results: Net Profit ₹566 Cr, Up 3.3% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,921 Cr (+54.8% YoY) and net profit of ₹566 Cr (+3.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹566 Cr · +3.3% YoY
Torrent Pharmaceuticals Management Change
Torrent Pharmaceuticals appointed Shanti Ekambaram as an Additional Independent Director. The appointment is for a three-year term effective July 30, 2026.